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Abstract
Several lines of evidence suggest that mitochondrial genetic factors may influence susceptibility to multiple sclerosis. To
explore this hypothesis further, we re-sequenced the mitochondrial genome (mtDNA) from 159 patients with multiple
sclerosis and completed a haplogroup analysis including a further 835 patients and 1,506 controls. A trend towards over-
representation of super-haplogroup U was the only evidence for association with mtDNA that we identified in these
samples. In a parallel analysis of nuclear encoded mitochondrial genes, we also found a trend towards association with the
complex I gene, NDUFS2. These results add to the evidence suggesting that variation in mtDNA and nuclear encoded
mitochondrial genes may contribute to disease susceptibility in multiple sclerosis.
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Introduction
Multiple sclerosis is a chronic inflammatory disease of the
central nervous system in which complex genetic factors exert a
profound influence on susceptibility. Although the pathogenesis of
the disease is unknown, there is considerable circumstantial
evidence implicating the involvement of mitochondria in mech-
anisms of axonal and glial injury [1,2]. Accordingly genes that
determine the function of these organelles are logical candidates
for susceptibility and influences on the clinical course.
Mitochondria are unique amongst cellular organelles for having
their own distinct genome, separate from that of nuclear DNA.
This mitochondrial genome (mtDNA) consists of a circular double
stranded DNA molecule which is 16,569 base pairs in length, and
contains a total of 37 genes - 2 ribosomal RNAs, 22 transfer RNAs
and 13 polypeptides. These 13 polypeptides are all components of
the respiratory chain, the core pathway in oxidative phosphory-
lation, the activity of which is the primary function of
mitochondria. A total of over 80 proteins make up the five
complexes in the respiratory chain, the remaining proteins being
encoded by genes in the nuclear genome. Since mtDNA is
inherited solely from the mother, it may be relevant that evidence
for a maternal parent of origin effect has been observed in multiple
sclerosis [3].
Perhaps the most compelling clinical evidence indicating a role
for mtDNA in determining susceptibility to multiple sclerosis
comes from the observation that some patients with mtDNA
mutations causing Leber’s hereditary optic neuropathy (LHON)
go on to develop a demyelinating disease which is clinically and
radiologically indistinguishable from multiple sclerosis (apart from
the prominence of visual failure) [4]. Evidence for mitochondrial
dysfunction in multiple sclerosis outside the context of LHON has
also been observed in functional imaging studies [5], pathological
analyses [2,6,7] and in the animal model of multiple sclerosis,
experimental autoimmune encephalomyelitis (EAE) [8].
Encouraged by these observations, several investigators [9–13]
have sequenced mtDNA from patients with multiple sclerosis in an
effort to identify relevant polymorphisms. As relatively few patients
were considered in these early studies, it is unsurprising that no
multiple sclerosis specific variation emerged. In addition to
sequencing mtDNA, selected mitochondrial polymorphisms have
also been tested for disease association in case-control cohorts
[10,11,14–20]. Here too the modest number of patients consid-
ered (typically ,100) has limited the power. The data regarding
haplogroups have been somewhat contradictory with some
researchers suggesting that haplogroups K and J increase risk
[17,21] while others have found evidence that haplogroup J/T is
protective [18]. The possible relevance of LHON related
mutations has understandably received attention and a suggestion
that secondary LHON mutations (mutations which are more
common in LHON but are not directly pathogenic for the
condition) increase the risk of multiple sclerosis has been suggested
[9,13,19,22] whilst another study showed a decreased risk [13].
Given this body of suggestive evidence implicating the
involvement of mitochondria in the pathogenesis of multiple
sclerosis, along with the limited power and extent of previous
efforts, we reasoned that a more extensive analysis of this
promising candidate was required.
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Subjects
All individuals included in this study are from the United
Kingdom, self reported as Caucasian and gave informed consent.
The study was approved by the Thames Valley Multi-Centre
Research Ethics Committee. In total we considered 937 trio
families (an affected individual and both parents), 96 additional
cases without available parental DNA and 671 unrelated healthy
controls (that have already been sequenced for their mtDNA). All
affected individuals satisfy Poser criteria [23] for the diagnosis of
multiple sclerosis. The demographic features of our affected
individuals are unexceptional with an average age of 38.6 years,
mean duration of disease of 11.9 years, mean EDSS of 4.3, and
gender ratio of approximately 3F:1M.
Mitochondrial re-sequencing
Re-sequencing of the mtDNA was carried out using a method
previously reported [24]. In summary specific primers were used
to sequence, in both the forward and reverse direction, 32
overlapping fragments which between them comprehensively
cover the entire mtDNA (primers are listed in Supplementary
Table S1). All sequencing reactions were performed using the
Applied Biosystems BigDyeH Terminator v3.1 cycle sequencing kit
according to the manufacturer’s recommended conditions.
Following the sequencing reaction, excess dye-terminators were
removed using AutoScreen-96A Well Plates (GE Healthcare).
Electrophoresis was performed on an Applied Biosystems 3700
DNA analyzer and the sequence was compared to the revised
Cambridge Reference Sequence (rCRS) [25] using SeqScape
software v 2.5 (Applied Biosystems). In the more restricted re-
sequencing of the hypervariable segment I (HVSI) region of the D-
loop alone, the same method was used but only the D1 and D2
primer-pairs considered.
Mitochondrial haplogroup typing
For each individual in which the mitochondrial genome was re-
sequenced the haplogroup was established based on defined
coding region polymorphisms according to Torroni et al [26] (see
Table 1). For those individuals that were only sequenced for the
HVSI region of the D-loop, haplogroups were classified according
to Simoni et al [27] and Richards et al [28] (see Table 2). In these
individuals, supplemental typing of the coding 7028, 9055 and
12308 variants was completed to more clearly define the H, U and
K groups.
Nuclear genome genotyping
In total 111 nuclear genome single nucleotide polymorphisms
(SNPs) were tested. All SNP genotyping was performed using
Applied Biosystems TaqMan methodology according to the
manufacturer’s recommended conditions. PCR was performed
on Applied Biosystems 384 well 9700 Viper PCR machines after
which genotypes were called on a 7900 High Throughput
Sequence Detection System using SDS software. Where available
Applied Biosystems Assay-On-Demand (AoD) products were used
(n=93); for all other variants, we used the Assay-By-Design (AbD)
service (n=18). Primers, basic marker performance measures and
single point transmission disequilibrium test (TDT) results as
determined using Unphased v3.08 [29] are available for each
marker in Supplementary Table S2.
All TaqMan assays were first tested against a panel of 378
samples. No workable assay could be designed for seven (6.3%)
variants and a further four (3.6%) were found to be non-
polymorphic (see Supplementary Table S2). The remaining 100
assays were typed in a total of 937 trio families. For each assay
duplicate typing was attempted in 163 individuals.
Statistical methods
In the haplogroup analysis, all haplogroups with a frequency of
,5% were considered together (resulting in a test with 5 degrees of
freedom). Association with individual mitochondrial variants was
assessed using Fishers Exact test. In the analysis of the SNPs from
the nuclear genome, Mendelian consistency was checked using the
Pedcheck program v1.1 [30], while deviation from Hardy-
Weinberg equilibrium, genotyping success rate and heterozygosity
was determined using the Pedstats program [31]. Transmission
Disequilibrium Testing (TDT) was performed using the Unphased
program v3.0.8 [29].
Results
Mitochondrial genome
To catalogue potentially relevant variation we first re-sequenced
the entire mitochondrial genome of 159 patients. In an effort to
enrich this initial re-sequencing experiment for mitochondrial
variants influencing susceptibility, we included 47 cases with an
Table 1. European haplogroup characterisation based on
coding region variants.
Haplogroup 7028 12308 9055 13368 16069
H C AG GC
JT A G G T
KT GA GC
TT A G A C
UT G GG C
Haplogroups were defined based on the variant present at each of these five
nucleotide positions. The nucleotides shown in bold represent the haplogroup
defining variant at that nucleotide position.
doi:10.1371/journal.pone.0002891.t001
Table 2. European haplogroup characterisation based on
HVSI variants.
Haplogroup HVSI variations (16024–163830)
H CRS
J 16069, 16126
K 16224, 16311
T 16126, 16294
U1a 189, 249
U1b 249, 327
U2 129C, 189, 362
U3 343
U4 356
U5 270
U7 318T
Haplogroups were defined based on a departure from the revised CRS at the
above sites. Typing of the coding region variants 7028, 9055 and 12308 was
completed to further confirm the H, U and K haplogroups.
doi:10.1371/journal.pone.0002891.t002
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affected sibling. By comparison with the rCRS, we identified a
total of 635 variants of which 62 were novel (see Supplementary
Table S3) in that they do not appear in the online databases
(Mitomap http://www.mitomap.org/ and the Human Mitochon-
drial Genome Databases http://www.genpat.uu.se/mtDB/).
These novel variants were identified in 47 cases and included 20
nonsynonymous, 29 synonymous, three tRNA, two rRNA and
eight non-coding substitutions. None of these novel variants were
seen in more than one individual. Considering the nine major
European haplogroups, only five (H, U, K, J and T) had a
frequency of greater than 5% in our cohort. No significant
difference in the frequency of these common haplogroups was
found when comparing our 159 cases with 671 healthy controls
(Table 3). Excluding cases and controls with haplogroups other
than the common five, left us with a sub-group of individuals
effectively matched for haplogroup background consisting of 140
cases and 607 controls. Association with individual variants,
present at a frequency of .5% in either the case or control
population, was tested within this haplogroup matched subgroup.
A total of 74 mtDNA variants were tested and the results for all
those showing nominal evidence for association at the 10%
significance level are shown in Table 4. Although none of these
associations survive Bonferroni correction for multiple testing, we
noticed that two of these potentially associated variants are from
the HVSI region. Therefore we decided to extend the investiga-
tion of this region by re-sequencing the HVSI region in an
independent cohort of 860 cases together with their unaffected
fathers. Re-sequencing failed in 25 individuals (overall sequencing
success rate of 98.5%) so that ultimately we had HVSI data from
835 case-father pairs. In an extension analysis of the 835 case-
father pairs plus the original 159 multiple sclerosis cases and 671
controls, we found a trend towards an over-representation of
super-haplogroup U (Table 3). Genotyping data from the multiple
sclerosis associated HLA-DRB1 gene was available in the majority
of cases and fathers. We found no evidence for any significant
excess in the frequency of the *1501 allele in individuals carrying
super-haplogroup U in either cohort. This independence from
*1501 indicates that our observed association is not secondary to
any effects of *1501.
We performed a stratified analysis based on phenotype by
including only patients with multiple sclerosis that had optic nerve
involvement, a phenotype known to be associated with mtDNA
variants. No clinical data were available for 119 samples and 202
patients showed no optic nerve involvement. A haplogroup
analysis of the remaining 673 patients compared to the controls
demonstrated a stronger association (p=0.007) with an overrep-
resentation of super-haplogroup U in the patients (Table 3).
None of the potentially associated variants from the HVSI
region identified in the screening phase showed any greater
Table 3. Haplogroup Frequencies.
Haplogroup Screening Phase
a Extension Phase
b Patients with optic nerve involvement
c
MS % (n=159) Controls % (n=671) MS % (n=994) Controls % (n=1506) MS % (n=673) Controls % (n=1506)
H 44.03 47.24 43.36 44.49 43.98 44.49
J 11.32 14.46 10.16 12.62 8.77 12.62
K 8.18 8.79 10.76 9.56 11.44 9.56
T 9.43 10.13 7.75 10.16 7.58 10.16
U 15.09 9.54 14.29 11.62 14.41 11.62
Other 11.95 9.84 13.68 11.55 13.82 11.55
ap=0.3450.
bp=0.0194.
cp=0.0073.
doi:10.1371/journal.pone.0002891.t003
Table 4. Nominally associated variations.
Site
Location in
genome Screening Phase Extension Phase Odds Ratio (95% CI)
Cases MAF %
(n=140)
Controls MAF %
(n=607) p-value
Cases MAF %
(n=858)
Controls MAF %
(n=1334) p-value
16093 D-loop 10.71 3.79 0.0021 8.63 5.40 0.0031 1.65 (1.18–2.32)
263 D-loop 97.14 89.95 0.0043 - - -
5004 ND2
a 5.00 1.65 0.0257 - - -
16270 D-loop 12.14 6.43 0.0309 10.4 8.02 0.0596 1.33 (0.99–1.78)
13617 ND5
a 11.43 6.75 0.0757 - - -
3197 16s rRNA 11.43 6.75 0.0758 - - -
9477 COIII
b 11.43 6.75 0.0758 - - -
Variations in individuals that were not designated to one of the 5 major haplogroups (H, J, T, U and K) were excluded from this analysis.
aSynonymous amino acid change.
bNon-synonymous amino acid change from valine to isoleucine.
doi:10.1371/journal.pone.0002891.t004
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found no evidence for heterogeneity at these markers across the
common haplogroups and thus unsurprisingly found no significant
change in the association when considering the common
haplogroups as separate strata in a Cochran-Mantel-Haenszel test
(results not shown). Three of the potentially associated variants
from table 4 that are not contained in the D-loop (13617, 3197
and 9477) were present in the same individuals all belonging to
haplogroup U. These three variants, like haplogroup U, were
over-represented in multiple sclerosis, indicating that they reflect
the same rather than different signals.
Nuclear encoded mitochondrial genes
In an analysis of mitochondrial dysfunction in multiple sclerosis,
Dutta et al [2] identified 23 nuclear encoded mitochondrial genes
that were found to have significantly altered expression in multiple
sclerosis. For each gene we used the HapMap browser release 20
(http://www.hapmap.org/cgi-perl/gbrowse/hapmap20_B35) to
select tagging SNPs that captured all of the common (greater
than 5%) variation within that gene. After a validation phase (see
methods), 100 nuclear genome SNPs were typed in 937 multiple
sclerosis trio families. A detailed list of the SNPs analysed is
available in Supplementary Table S2. Six SNPs showed evidence
of association with nominal significance (Table 5) and four of these
reside in the NDUFS2 gene which is part of Complex I. None of
these signals survived even modest Bonferroni correction;
nevertheless the four NDUFS2 SNPs are in tight linkage
disequilibrium with each other, making it unlikely that these data
reflect a genotyping error.
Discussion
The aim of this study was to assess whether mitochondrial
genes, both nuclear and mitochondrial encoded, are involved in
susceptibility to multiple sclerosis. Haplogroup analysis of the
mitochondrial genome identified a trend towards an over-
representation of super-haplogroup U. In addition we also found
modest evidence of an association with variations in the nuclear
gene NDUFS2.
In our analysis of the five most common haplogroups, the
finding of a trend towards an over-representation of super-
haplogroup U (which encompasses haplogroups U and K) and an
under-representation of the J/T haplogroup in cases, is in line with
a study of multiple sclerosis cases in the Basque people [18].
Restricting the analysis to those patients with optic nerve
involvement strengthened the significance. This finding warrants
more detailed assessment in a larger replication cohort of patients
in order to distinguish a genuine effect specific to this multiple
sclerosis phenotype from a chance finding due to sampling
variance. Although our study is one of the largest to have
investigated the role of mtDNA haplogroups in multiple sclerosis,
it is important to point out that its power is still relatively limited.
Even considering a modest 5% significance level, the power curves
we have previously described [32] indicate that we were only able
to detect (90% or better) common haplogroups conferring a
relative risk of .1.6 and that we had almost no power to
demonstrate association with any common haplogroups influenc-
ing risk by a factor of ,1.4. Our data make it unlikely that any
common mitochondrial haplogroup exerts a substantial risk but
that conclusion does not exclude the possibility of more modest
effects, similar to those seen with nuclear genes, whereby risk
factors of the order of 1.2 have certainly not been excluded.
In an analysis of individual variants from the mitochondrial
genome there were no significant findings. Of the mtDNA variants
which showed nominal evidence for association in the screening
phase, two in the HVSI region, which were screened in a larger
cohort, showed reduced evidence for association. Similar power
limitations to those described above apply to our analysis of these
other mtDNA variants (and the nuclear variants), and these
limitations are intensified in the screening phase where only a
modest number of cases (n=159) was considered.
In this study none of the three primary LHON mutations (at
nucleotide position 3460, 11778 and 14484) were carried by any of
the patients and we found no evidence for association with any of
the secondary LHON mutations (4216, 13708 and 14798). Our
results differ to those reported in a recent study in Bulgarian
multiple sclerosis patients which showed evidence for an
association with the secondary LHON mutation 4216C [19]. In
the present study the 4216C allele was present in 24.3% and
27.2% of cases and controls respectively (p=0.5256), the observed
trend being in the opposite direction to that identified in the
Bulgarian study [19].
Our analysis of nuclear encoded variants shows a trend
suggesting the possible involvement of the NDUFS2 gene from
Complex I. This complex is the main mediator of the production
of mitochondrial super oxide [33] and is involved in ATP synthesis
through the generation of a proton gradient. It is the first and
largest subunit involved in the electron transport chain and is
comprised of two parts, a hydrophilic catalytic peripheral arm
which protrudes into the matrix and is where electron transport
occurs and the hydrophobic membrane arm embedded in the
mitochondrial matrix and utilised for proton translocation [34].
The flavoproteins and the iron sulphur protein subunits (of which
NDUFS2 is one) are hydrophilic, with the remaining nuclear and
mitochondrial encoded subunits forming the hydrophobic part.
Mutations in the NDUFS2 gene have been shown to result in a
decreased activity of Complex I due to defects in the assembly and
stability of this complex, and these also affect the stability of
Complex III but without reducing its activity [34]. Aside from
altered energy production, a disruption in Complex I may also
affect the elimination of autoreactive T cells. Mitochondrial
encoded proteins are essential for activation induced T cell death
(AICD). Specifically Complex I is involved in the generation of
reactive oxygen species (ROS) and thus the induction of AICD, an
important regulator of autoimmunity, via increased expression of
CD95L [35]. Given the role of CD95L in the development of T
cells and induction of AICD, mitochondrial damage could result
in impaired thymocyte development and the inability to eliminate
auto-reactive T cells.
In summary we have completed the largest study to date
considering the role of mtDNA and nuclear encoded mitochon-
drial genes in susceptibility to multiple sclerosis. Our findings
provide some support that super-haplogroup U may be a risk
Table 5. Markers showing nominally significant TDT results.
Gene Chromosome Marker p-value
a Odds Ratio (95% CI)
NDUFS2 1 rs3924264 0.00398 1.23 (1.06–1.43)
NDUFS2 1 rs1136224 0.00865 1.29 (1.06–1.56)
NDUFS2 1 rs3813624 0.0238 1.25 (1.02–1.54)
NDUFS2 1 rs4656994 0.0278 1.19 (1.01–1.40)
ATP5J 21 rs3761326 0.0324 1.22 (1.01–1.47)
ATP5G3 2 rs268230 0.0324 1.21 (1.02–1.42)
aUncorrected.
doi:10.1371/journal.pone.0002891.t005
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towards an association with the NDUFS2 gene in the Complex I
pathway, providing further support that this may be disrupted in
multiple sclerosis patients. Further analysis of this gene as well as
others in the Complex I pathway is required.
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